TB incidence peaked within six months of HAART initiation, and dropped from 3.3/100 person-years in the first year to 0.4/100 person-years in the fifth year. At baseline, risk factors associated with TB included WHO clinical stage 3 HIV infection (adjusted hazard ratio (AHR) 2.53; 95%CI 1.70-3.70), WHO clinical stage 4 HIV infection (AHR, 3.86; 95%CI 2.54-5.86), and patients who were bed ridden >50%a day (AHR, 1.52; 95%CI 1.13-2.05). The rate of mortality was 6.9%(incidence 2.8 per 100 person-years) and 57%of deaths occurred in the first six months of HAART initiation. Multivariate Cox model indicated WHO clinical stage 4 HIV infection, CD4+ cell count <50 cells/渭l, bed ridden >50%a day, and TB after HAART initiation as baseline independent predictors of mortality. Additional evidence shows that regular CD4+monitoring of patients before HAART initiation as well as earlier HAART initiation decreases death, and regular clinical staging decreases TB incidence.